67.10
-0.90
(-1.32%)
May 24 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 67.10 - 68.34 |
| 52 week | 39.00 - 84.25 |
| Open | 68.00 |
| Vol / Avg. | 18,084.00/1,071.00 |
| Mkt cap | 51.97M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.03* |
| Shares | 77.45M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
May 7, 2013
Futura Medical PLC Annual General Meeting
Mar 7, 2013
Preliminary 2012 Futura Medical PLC Earnings Presentation (London)
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | - | -2902.20% |
| Operating margin | - | -3274.57% |
| EBITD margin | - | -3271.67% |
| Return on average assets | -89.92% | -70.67% |
| Return on average equity | -100.01% | -77.31% |
| Employees | 3 | - |
| Carbon Disclosure Rating | - | - |
Address
Surrey Technology Centre, 40 Occam Road
GUILDFORD, ENG GU2 7YG
United Kingdom - Map
+44-1483-685670 (Phone)
+44-1483-685671 (Fax)
GUILDFORD, ENG GU2 7YG
United Kingdom - Map
+44-1483-685670 (Phone)
+44-1483-685671 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Futura Medical plc (Futura) develops products for the consumer healthcare market. The Company�s principal activity includes research and development of medical devices and pharmaceutical drugs and their commercial exploitation with the focus being on transdermal products for sexual healthcare and pain relief management. Futura�s sexual healthcare products included CSD500, PET500 and MED2002. Its pain relief management included TPR100 and TPR100-Rx. Futura has developed a transdermal delivery technology, DermaSys, for the absorption of active molecules through the skin. CSD500 is aimed at helping men maintain a firmer erection during intercourse whilst wearing a condom. MED2002 is a topical gel for the treatment of male erectile dysfunction. TPR100 is a product for the provision of topical pain relief. TPR100-Rx is a topical product available on prescription for the treatment of more profound indications, such as osteoarthritis and rheumatic pain.
Officers and directors
| James Henry Barder | Chief Executive, Executive Director | |
| Derek Adrian Martin | Finance Director, Company Secretary, Executive Director | |
| David B. Davies | Chief Development Officer, Executive Director | |
| John Clarke | Non-Executive Chairman of the Board | |
| Lisa Arnold | Independent Non-Executive Director | |
| Jonathan David Freeman | Senior Independent Non-Executive Director |
